PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 1, 2020Journal for ImmunoTherapy of Cancer274 citationsOpen Access

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

ACAlessio CortelliniMTMarco TucciVAVincenzo Adamo

Key Points

Key points are not available for this paper at this time.

Abstract

We confirmed the association between baseline steroids administered for cancer-related indication, systemic antibiotics, PPIs and worse clinical outcomes with PD-1/PD-L1 checkpoint inhibitors, which can be assumed to have immune-modulating detrimental effects.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Cortellini et al. (2020) studied this question.

synapsesocial.com/papers/69d74e0cb1cb92dd1bb8a661https://doi.org/10.1136/jitc-2020-001361
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?2020 · 72 citations
  2. 2Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis2012 · 30 citations
  3. 3Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans2019 · 593 citations
  4. 4Treatment of Elderly Patients With Non–Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology2015 · 72 citations
  5. 5The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights2010 · 1,824 citations